Reports Q4 revenue $57.584M, consensus $57.44M. “We are pleased with our continued growth throughout 2025, leveraging the efficiency of our GI-focused strategy,” said Steven Basta, President and Chief Executive Officer of Phathom. “Revenue increased significantly over the last three quarters. In the fourth quarter, we realigned our sales organization and enter 2026 with a stronger sales team and marketing initiatives designed to deepen engagement and increase prescribing for GERD across gastroenterologists.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals Announces $130 Million Public Offering
- Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00
- Closing Bell Movers: Defense stocks surge on Trump military budget comments
- Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M
- Phathom Pharmaceuticals announces common stock offering, no amount given